Anti-Inflammatory drug may boost chemo for aggressive lymphoma
NCT ID NCT07494565
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the anti-inflammatory drug celecoxib to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed, advanced CD5-positive diffuse large B-cell lymphoma (a fast-growing type). Sixty participants will be randomly assigned to receive either celecoxib plus R-CHOP or R-CHOP alone. The main goal is to see if the combination leads to more complete remissions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Celecoxib (an anti-inflammatory drug) combined with R-CHOP chemotherapy
What this could lead to
If it works, this could improve the chance of complete remission for people with a hard-to-treat type of lymphoma.
What could go wrong
This is a small, early-phase trial (60 people) and may not show a clear benefit. Adding celecoxib could also increase side effects like stomach or heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China